Large drugmakers to be active in R&D

Published: 2007-01-18 07:00:00

Updated: 2007-01-18 07:00:00

Domestic big pharmaceutical firms are expected to focus on their research and development (R&D) sector this year in an attempt to cope with a new harsh environments involving the FTA and the government's new drug pricing policy, so-called "positive list system, according to pharmaceutical busines...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK